Tirzepatide Tops Liraglutide and Semaglutide for Obesity Without Diabetes

Obesity is a global health crisis, significantly increasing the risk of numerous chronic conditions, but effective pharmacological treatments are crucial. GLP-1 receptor agonists like Liraglutide and Semaglutide, and the dual GLP-1/GIP receptor agonist Tirzepatide, have shown promise in weight management. However, a clear, direct comparative assessment of their efficacy and safety in patients with obesity but without concomitant Type 2 Diabetes (T2D) has been lacking.

The network meta-analysis revealed significant differences in efficacy and safety profiles among the three agents. Tirzepatide consistently demonstrated superior weight loss compared to both Semaglutide and Liraglutide. Participants on Tirzepatide achieved an average body weight reduction of 20.9% from baseline, significantly higher than Semaglutide at 15.2% and Liraglutide at 8.1% (all comparisons vs. placebo, p<0.001). Gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common, with Tirzepatide showing a slightly higher incidence of nausea (35%) compared to Semaglutide (30%) and Liraglutide (25%), though these were generally mild to moderate. Tirzepatide was identified as the most effective treatment for weight reduction in non-diabetic obese patients, demonstrating a 5.7% greater weight loss than Semaglutide and a 12.8% greater weight loss than Liraglutide.